Blog Posts Assessing Potential Risks in the Consideration of IND Exemption Criteria Read More about Assessing Potential Risks in the Consideration of IND Exemption Criteria
Blog Posts Defining “Minimal Risk” in Clinical Research Read More about Defining “Minimal Risk” in Clinical Research
Blog Posts Highlighting the Growing Importance of Institutional Biosafety Committees in Clinical Research Read More about Highlighting the Growing Importance of Institutional Biosafety Committees in Clinical Research
Blog Posts Managing the Shortage of Contrast Agents in Clinical Research Studies Read More about Managing the Shortage of Contrast Agents in Clinical Research Studies
Blog Posts WCG IRB’s Single-Patient Expanded Access Experience Before and During the COVID-19 Pandemic Read More about WCG IRB’s Single-Patient Expanded Access Experience Before and During the COVID-19 Pandemic
Blog Posts Using an IRB’s Site Relationships to Relieve “Site Crunch” and Reduce Trial Pressures Read More about Using an IRB’s Site Relationships to Relieve “Site Crunch” and Reduce Trial Pressures
Blog Posts Key Takeaways From FDA’s New Draft Guidance, “Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial” Read More about Key Takeaways From FDA’s New Draft Guidance, “Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial”
Blog Posts Compensating Research Participants FAQ Read More about Compensating Research Participants FAQ
Blog Posts Four Key Elements You Need to Know About the Role of IBCs in Gene Therapy Trials Read More about Four Key Elements You Need to Know About the Role of IBCs in Gene Therapy Trials